Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.
about
A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis.Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report.Cyclophosphamide and lupus nephritis: when, how, for how long?Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitisMetabolism and transport of oxazaphosphorines and the clinical implications.Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.Urinary proteomics: a tool to discover biomarkers of kidney diseases.Water intoxication induced by low-dose oral cyclophosphamide in a patient with anti-neutrophil cytoplasmic antibody-related glomerulonephritis.Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option.Improving outcomes in patients with lupus and end-stage renal disease.Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.Treatment of proliferative lupus nephritis: a slowly changing landscape.Impact of glomerular kidney diseases on the clearance of drugs.Pharmacokinetic modeling of therapies for systemic lupus erythematosus.Cyclophosphamide in dermatology.Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review.SJSZ glycoprotein (38 kDa) modulates expression of IL-2, IL-12, and IFN-γ in cyclophosphamide-induced Balb/c.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.[Dosage and toxicity of antirheumatic drugs in renal insufficiency].Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice.12. The Urinary Proteomics: A Tool to Discover New and Potent Biomarkers for Kidney Damage.Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis.ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.Predicting concentrations of the cytostatic drugs cyclophosphamide, carboplatin, 5-fluorouracil, and capecitabine throughout the sewage effluents and surface waters of Europe.Successful allo-SCT in a Fanconi anemia patient with renal impairment using reduced doses of CY and fludarabine.Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis.Discontinuation of Hemodialysis in a Patient with Anti-GBM Disease by the Treatment with Corticosteroids and Plasmapheresis despite Several Predictors for Dialysis-Dependence.Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes.Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis - a single institution experience.Sequential renal and bone marrow transplants in a child with Fanconi anemia.Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis.Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN).
P2860
Q30317533-40DF823D-3264-4E7C-8163-3FB7A03EBD8CQ33427666-B21A6714-B24D-4481-9B5D-7A3813CF66B5Q34095231-A713091C-2F98-443B-9F8D-A5BD58F81B55Q35891359-B84A7A78-CFDE-45D4-B7E1-D535ED0B80DAQ36336024-633F8274-567F-4DDB-BF51-B6265254B694Q36360811-AD795055-FEF4-434B-8765-648B5025BAB5Q36511158-CA5ADAE4-D0E7-4B08-B646-7C93357AF9A4Q36731380-88DE884F-D9CA-4BFC-8E74-A7A94661EF11Q36873930-1BA16170-C176-4097-A281-C5E388683287Q37415711-A922D64E-AF4E-43F6-A38D-8475F2D00376Q37522782-07B0BB7A-2C0B-4126-A21F-AE974F09B5ADQ37684587-953A7499-807E-4520-8149-1192C1B333C6Q37822658-2FB2FFE8-B131-43D0-A92B-72E72256C7FEQ37974647-3E603EC2-AD13-4FB7-8B0E-FC4548B2E322Q38542910-E0510BF8-1F00-4F7B-92DB-991FDC8BD49AQ38710150-38BCCE2A-E964-4B48-829F-B87B46FC937FQ38969688-B04D8C65-9053-41B0-9E22-E5B8DC002509Q39311661-C8A49FDD-7240-4412-8004-89F5155E56C9Q40772216-DC71BC99-DD8C-4032-A457-17FA6CF4D2A2Q41241653-3E5B180A-9DBA-4630-BDBC-20BBCCCCE652Q41349270-2DB6B78B-2618-4D8C-ADBF-0A408A70316BQ41650221-F0B259FB-B072-4B2A-B390-851FC7582779Q41858062-37E0FB8A-9198-49AC-89E8-0DFF05F7DEACQ45084231-D91B231B-9C3D-4B95-96DD-C850E1447E65Q45197360-8295B5A6-7DAA-4F96-822D-4B25F8F25823Q45393326-80C0A725-A1FF-4500-92C3-AA6B920A5747Q45929969-B035D752-8593-436F-A191-F5DE9D24EE0AQ45958144-F64BA9C3-9AA1-4686-AB49-BD2678386DF0Q47156066-D328FA1A-66C0-45FE-974F-CCD6D983D930Q49691317-4E49BFA1-9B44-4C34-AA7F-ADF26297657FQ52858430-0B13136B-29F1-448E-89D1-D6850951C323Q52908667-6004CE9D-866D-49AE-A404-EDB3DC501E7BQ53251807-F4AE7880-71F9-42DD-AB79-F5EE4B80A582Q53806024-BD14863E-5ED4-4C56-8DCD-509D9B13F71CQ55019941-8C5124BF-470F-4D86-9EFA-32169FE086EB
P2860
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@ast
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@en
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@nl
type
label
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@ast
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@en
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@nl
prefLabel
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@ast
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@en
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@nl
P2093
P1433
P1476
Cyclophosphamide pharmacokinet ...... ents with renal insufficiency.
@en
P2093
Dagmar Busse
Frank Bohnenstengel
Marion Haubitz
Matthias Schwab
Reinhard Brunkhorst
P304
P356
10.1046/J.1523-1755.2002.00279.X
P407
P50
P577
2002-04-01T00:00:00Z
P5875
P6179
1038003170